Angelman Syndrome Study

The purposes of this study are to gain a better understanding of the disease progression of Angelman syndrome, to follow the natural history of the clinical features of Angelman syndrome and to gain a better understanding of the clinical differences between the various genetic mechanisms of Angelman syndrome.

Eligible participants include individuals from birth to 60 years who have had genetic testing and have a documented molecular diagnosis of Angelman syndrome OR patients with a clear clinical diagnosis of Angelman syndrome who do not have a known molecular defect.

For more information, see the Angelman syndrome study fact sheet or contact This email address is being protected from spambots. You need JavaScript enabled to view it. , study coordinator.

Greenwood Genetic Center is also an approved site for a Phase 2 Randomized Placebo-Controlled Trial of Levodopa in Angelman Syndrome.

Official Study Website

Rare Disease Network